Biotechs' Rocky Road

Biotechs have taken a bit of a beating of late, with the Nasdaq Biotechnology Index off 18% from its high in February and flat for the year.

There doesn't seem to be any one thing to blame. Instead it's a combination of little things like worry over drug pricing and investors locking in gains after a long run.

Despite the tempered feelings about the sector, there's still growth to be had. Gilead Sciences (NASDAQ: GILD  ) should come close to generating its entire market cap in cash over the next seven years. But investors should be careful when looking at companies such as Orexigen (NASDAQ: OREX  ) and GW Pharma (NASDAQ: GWPH  ) , which have shot up on limited news.

Watch the video below where senior biotech specialist Brian Orelli and health-care bureau chief Max Macaluso discuss the prospects for Gilead, Orexigen, GW Pharma, and the rest of the industry.

The high-tech industry just keeps on giving
If you thought the iPod, the iPhone, and the iPad were amazing, just wait until you see this. One hundred of Apple's top engineers are busy building one in a secret lab. And an ABI Research report predicts 485 million of them could be sold over the next decade. But you can invest in it right now... for just a fraction of the price of AAPL stock. Click here to get the full story in this eye-opening new report.


Read/Post Comments (2) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 26, 2014, at 3:49 AM, marp11 wrote:

    with Lilly now going after Takada for stiffing them 6 billion...OREX can forget what marketing help they were expecting.

    Takada has no money or time to start a new deal.

    Besides Contrave is still 2 old generics combined with horrible side effects. 27% dropped out of the trials.

    Orex suffers same fate as VVUS.

    ARNA is busting all doors open with savvy media blitz.

    BELVIQ is blockbuster

  • Report this Comment On April 28, 2014, at 9:14 AM, marp11 wrote:

    another brilliant osmelli call

    GWPH

    fools

    ARNA $50 by xmas

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2931095, ~/Articles/ArticleHandler.aspx, 8/22/2014 11:55:22 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 17,012.97 -26.52 -0.16%
S&P 500 1,988.72 -3.65 -0.18%
NASD 4,537.69 5.59 0.12%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/22/2014 11:39 AM
GILD $104.15 Up +1.88 +1.84%
Gilead Sciences CAPS Rating: ****
GWPH $90.40 Up +1.35 +1.52%
GW Pharmaceuticals… CAPS Rating: **
OREX $5.66 Down -0.03 -0.44%
Orexigen Therapeut… CAPS Rating: **

Advertisement